HLA antibody screening market seen reaching $1.47B by 2030

By AI, Created 4:50 PM UTC, May 18, 2026, /AGP/ – The global human leukocyte antigen antibody screening market is projected to grow to $1.47 billion by 2030 as transplant volumes rise and screening technology improves. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - HLA antibody screening helps match organ donors and recipients more precisely, which can lower rejection risk and improve transplant outcomes. - Rising transplant volumes and end-stage disease rates are expanding demand for pre-transplant immunological testing. - The market’s growth reflects broader pressure on health systems to improve transplant success and make better use of scarce donor organs.

What happened: - The Business Research Company forecast the human leukocyte antigen antibody screening market will rise from $1.06 billion in 2026 to $1.47 billion by 2030. - The report puts the market on an 8.6% compound annual growth rate during the forecast period. - The report also estimates the market grew from $0.98 billion in 2025 to $1.06 billion in 2026, an 8.4% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region through the forecast period.

The details: - The market has been supported by more organ transplant procedures, higher rates of end-stage organ failure, stronger awareness of transplant rejection risks, expansion in transfusion medicine, and improvements in immunoassay platforms. - The forecast period is being driven by demand for more precise transplant matching, wider use of multiplex bead-based assay technologies, more spending on transplant immunology research, expansion of transplant programs in emerging economies, and automated HLA antibody screening systems. - The report highlights single antigen bead assays for higher sensitivity, broader pre-transplant immunological risk assessment, higher-throughput flow cytometry screening, post-transplant antibody monitoring, and standardization of HLA antibody detection methods as key trends. - HLA antibody screening is a laboratory test that identifies antibodies against human leukocyte antigen molecules in a patient’s blood. - Those antibodies can develop after blood transfusions, pregnancy, or prior organ transplants. - Detecting those antibodies helps assess sensitization and transplant compatibility risk. - In January 2025, the US Department of Health and Human Services’ Health Resources and Services Administration reported lung transplant operations increased 10.4%, from 3,026 in 2023 to 3,340 in 2024. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report offers a free sample and the full market report.

Between the lines: - The report points to a market that is moving from basic testing toward more automated, higher-throughput and more standardized screening. - Faster growth in Asia-Pacific suggests transplant infrastructure and testing adoption are spreading beyond mature markets. - The jump in lung transplant procedures is one concrete signal that screening demand is tied closely to procedure volumes, not just general diagnostics spending.

What’s next: - Market growth is expected to continue as transplant programs expand and immunology testing becomes more automated. - Adoption of multiplex bead-based assays and post-transplant monitoring protocols is likely to broaden as hospitals seek better risk detection. - Emerging markets may add momentum if transplant access and testing capacity continue to scale.

The bottom line: - HLA antibody screening is becoming a more important part of transplant care, and the market is on track for steady growth through 2030.